Tykerb - Dual Tyrosine Kinase Inhibitor for the Treatment of Solid Tumours

 

Key Data:

Drug (Brand/Generic)
Tykerb/Tyverb/Lapatinib ditosylate
Company/Licensee
GlaxoSmithKline
Therapy Class
TKI
Product Description
Dual-acting TKI that targets erbB1 and erbB2
Current Indication
Breast cancer
Market Sector
Oncology
Development Status
Approved US and Europe



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development